SCHEMBL19253831

SCHEMBL19253831

COC(=O)CNCc1ccc(F)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
DPP4 P27487 1/20 0.40
PDE10A Q9Y233 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
GYS1 P13807 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
VNN1 O95497 1/20 0.40
P2RX7 Q99572 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31696726 0.88 KMT2A (0.41) MEN1KMT2AALDH1A1HDAC3HDAC1
SCHEMBL16858535 0.86 MEN1 (0.52) MEN1KMT2AALDH1A1ROCK2ROCK1
SCHEMBL12095339 0.81 GYS1 (0.44) MEN1KMT2AALDH1A1HDAC3HDAC1
SCHEMBL2891362 0.81 CA12 (0.54) MEN1KMT2AALDH1A1HDAC3HDAC1
SCHEMBL30639470 0.80 ALDH1A1 (0.56) MEN1KMT2AMAOAMAOBALDH1A1
SCHEMBL1717077 0.80 ALDH1A1 (0.56) MEN1KMT2AMAOAMAOBALDH1A1
SCHEMBL16702357 0.79 MEN1 (0.48) MEN1KMT2AALDH1A1
SCHEMBL24178929 0.79 ERCC1 (0.51) ALDH1A1LMNAHPGD
SCHEMBL31495524 0.79 NPC1 (0.47) MEN1KMT2AALDH1A1LMNAHPGD
SCHEMBL5004061 0.78 ALDH1A1 (0.54) MEN1KMT2AALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10532985-B2 Heterocycle and carbocycle derivatives having TRKA inhibitory activity SHIONOGI & CO., LTD. (JP) 2020-01-14 US disclosed
US-10160727-B2 Heterocycle and carbocycle derivatives having TrkA inhibitory activity SHIONOGI & CO., LTD. (JP) 2018-12-25 US disclosed
US-20170240512-A1 HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2017-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160727-B2 Heterocycle and carbocycle derivatives having TrkA inhibitory activity NR5A2, NPY5R, MC5R MEN1 3005/4885KMT2A 1684/4885MAOA 1076/4885
US-10532985-B2 Heterocycle and carbocycle derivatives having TRKA inhibitory activity NR5A2, NPY5R, MC5R MEN1 3005/4885KMT2A 1684/4885MAOA 1076/4885
US-20170240512-A1 HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY NR5A2, NPY5R, MC5R MEN1 3005/4885KMT2A 1684/4885MAOA 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.